Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.

[1]  B. Lavina,et al.  PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. , 2012, Journal of hepatology.

[2]  D. Rockey,et al.  Complications of cirrhosis , 2012, Current opinion in gastroenterology.

[3]  Shou-Dong Lee,et al.  Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[4]  B. Lavina,et al.  Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. , 2011, Journal of hepatology.

[5]  V. De Luca,et al.  The leader peptide of a human rec. MnSOD as molecular carrier which delivers high amounts of Cisplatin into tumor cells inducing a fast apoptosis in vitro , 2011, International journal of cancer.

[6]  F. Lammert,et al.  Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.

[7]  Mercedes Fernandez,et al.  Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. , 2010, Journal of hepatology.

[8]  M. Mizukami,et al.  Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. , 2009, Transplantation proceedings.

[9]  M. Mejías,et al.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.

[10]  L. Mazzarella,et al.  Biophysical and biochemical characterization of a liposarcoma‐derived recombinant MnSOD protein acting as an anticancer agent , 2008, International journal of cancer.

[11]  J. García-Pagán,et al.  Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension , 2008, Gut.

[12]  Shou-Dong Lee,et al.  Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis. , 2008, Journal of hepatology.

[13]  Mercedes Fernandez,et al.  Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability , 2007, Hepatology.

[14]  M. Mejías,et al.  Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats , 2007, Hepatology.

[15]  R. Groszmann,et al.  Vascular endothelial dysfunction in cirrhosis. , 2007, Journal of hepatology.

[16]  M. Tommasino,et al.  Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line , 2006, International journal of cancer.

[17]  R. Groszmann,et al.  The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule , 2006, Hepatology.

[18]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[19]  S. Friedman,et al.  Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis , 2004, Gut.

[20]  F. Nevens,et al.  Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls , 2003, Comparative hepatology.

[21]  J. Rodés,et al.  Cyclooxygenase‐derived products modulate the increased intrahepatic resistance of cirrhotic rat livers , 2003, Hepatology.

[22]  J. Rodés,et al.  5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. , 2002, Gastroenterology.

[23]  P. Pizcueta,et al.  The role of portal pressure in the severity of bleeding in portal hypertensive rats , 2000, Hepatology.

[24]  M. Toruner,et al.  Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. , 1999, Gastroenterology.

[25]  T. Gupta,et al.  Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats , 1998, Hepatology.

[26]  D. Rockey,et al.  Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. , 1998, Gastroenterology.

[27]  F. D'armiento,et al.  A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells. , 2009, Free radical biology & medicine.

[28]  R. Groszmann,et al.  Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. , 2006, Journal of hepatology.

[29]  J. Bosch,et al.  Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.